Cantor Fitzgerald Weighs in on Immatics FY2026 Earnings

Immatics (NASDAQ:IMTX) – Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Immatics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings of ($1.50) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share.

Other equities research analysts also recently issued reports about the company. Wall Street Zen downgraded Immatics from a “hold” rating to a “strong sell” rating in a report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft assumed coverage on Immatics in a report on Wednesday, May 28th. They issued a “buy” rating and a $10.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Immatics has a consensus rating of “Moderate Buy” and an average price target of $14.67.

Immatics Trading Up 0.3%

Shares of Immatics stock opened at $5.96 on Tuesday. The stock’s fifty day simple moving average is $4.81 and its 200 day simple moving average is $5.48. The company has a market capitalization of $724.44 million, a PE ratio of -9.03 and a beta of 0.83. Immatics has a 12 month low of $3.30 and a 12 month high of $13.69.

Immatics (NASDAQ:IMTX) last issued its earnings results on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The company had revenue of $20.12 million during the quarter, compared to analysts’ expectations of $14.92 million.

Institutional Investors Weigh In On Immatics

Several large investors have recently modified their holdings of the business. Vestal Point Capital LP increased its holdings in shares of Immatics by 14.6% in the first quarter. Vestal Point Capital LP now owns 7,192,700 shares of the company’s stock worth $32,439,000 after acquiring an additional 917,700 shares in the last quarter. Trexquant Investment LP acquired a new position in shares of Immatics during the first quarter worth about $783,000. Pale Fire Capital SE boosted its position in shares of Immatics by 8.9% during the first quarter. Pale Fire Capital SE now owns 34,270 shares of the company’s stock worth $155,000 after buying an additional 2,808 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in shares of Immatics by 38.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 14,677,003 shares of the company’s stock worth $66,194,000 after buying an additional 4,072,226 shares during the period. Finally, Algert Global LLC boosted its position in shares of Immatics by 20.6% during the first quarter. Algert Global LLC now owns 70,668 shares of the company’s stock worth $319,000 after buying an additional 12,072 shares during the period. 64.41% of the stock is currently owned by institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.